VirExit Technologies

VirExit Technologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of VirExit Technologies (VXIT) as of Nov 4, 2026 is 2.18 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -5.73 % — a change of -138.03% (higher).

FCF Conversion

2.18 %

YoY

-138.03%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of VirExit Technologies is 2024 2.18 % . FCF Conversion Rate (FCF/EBITDA) of VirExit Technologies was 2023 -5.73 % . It decreases by -138.03% higher compared to the previous year.

The VirExit Technologies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
66.17 USD
Jan 1, 2018
34.64 USD
Jan 1, 2019
5.75 USD
Jan 1, 2020
2.97 USD
Jan 1, 2021
15.67 USD
Jan 1, 2022
9.87 USD
Jan 1, 2023
-5.73 USD
Jan 1, 2024
2.18 USD
The VirExit Technologies FCF Conversion history
YEARFCF ConversionYoY
2.18 %-138.03%
-5.73 %-158.07%
9.87 %-37.04%
15.67 %+428.19%
2.97 %-48.39%
5.75 %-83.41%
34.64 %-47.65%
66.17 %+101.59%
32.83 %-9.61%
36.32 %+216.56%
11.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

VirExit Technologies Stock analysis

What does VirExit Technologies do? VirExit Technologies, Inc. generates revenue through its branded products and services, including disinfectant cleaners, antiviral medications, personal protective equipment (PPE), and sterilization systems under the VirExit(r) and VirExit.com brands. The company targets buyers seeking protective solutions for individual, community, and local economic needs in rural and peri-urban areas globally. Its Lexian product, an Ultraviolet-C-based device, is marketed as a sterilization system for disabling viruses and bacteria through optical diffusion. The firm operates a vertical online marketplace as a primary sales and marketing platform, connecting buyers and sellers of protective products and services. This platform serves as a single source for customers requiring disinfectants, medications, PPE, and sterilization systems. VirExit(r) and VirExit.com are the key brands driving product visibility and sales across its target segments. VirExit Technologies focuses on rural and peri-urban markets worldwide, where it incubates franchise business concepts to support local economies. The company's offerings are designed to address health and safety needs, with Lexian positioned as a specialized sterilization solution. Its business model integrates product sales, franchise incubation, and an online marketplace to serve both individual and community-level demand. VirExit Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about VirExit Technologies stock

FCF Conversion Rate (FCF/EBITDA) of VirExit Technologies is 2.18 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of VirExit Technologies changed from -5.73 % to 2.18 %, representing a -138.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) VirExit Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s VirExit Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — VirExit Technologies

All Key Metrics — VirExit Technologies